BALTIMORE, MD, November 12, 2024 – New research in the INFORMS journal Manufacturing & Service Operations Management is guiding the development of more inclusive and efficient electricity markets. The work demonstrates how aggregating small-scale, distributed energy resources (DERs) like solar panels can effectively balance the power of large utility companies.
Global supply chains are undergoing an irrevocable shift. While material flows remain critical, they are only the most visible aspect of this transition. Beneath the surface, changes in information exchanges, financial reconfigurations, and human capital movements are posing far greater risks to the benefits of global trade. The US, China, and the rest the world must handle these changes with care and perspective.
An audio journey of how data and analytics save lives, save money and solve problems.
Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
[email protected]
443-757-3578
Explore our resources for multiple topics including:
Two drug companies have now reported highly successful results from phase III trials of COVID-19 vaccines. On November 18 Pfizer and partner BioNTech said their vaccine was 95 percent effective at preventing the disease, based on full trial results. Two days earlier Moderna reported its vaccine was 94.5 percent effective, based on interim data.
It’s probably not exactly what President Donald Trump meant when he borrowed the historic jingoistic slogan “America First” for his administration, but since early in the global COVID-19 pandemic, the U.S. has consistently held the Number One spot in coronavirus cases and deaths. It took less than two months for these numbers to grow from 200,000 to a mind-boggling 250,000 now.
Operation Warp Speed, a Trump administration initiative to manufacture COVID-19 vaccines as fast as possible, should be lauded as a successful endeavour in what has otherwise been a poor effort to deal with the coronavirus, experts say. "No doubt, Operation Warp Speed is a huge success," said Tinglong Dai, associate professor of Operations Management and Business Analytics at Johns Hopkins University Carey Business School in Baltimore.
Reports of spiking COVID-19 cases and related fatalities have been met with recent news of extremely promising vaccines developed by Pfizer and Moderna. With the two offerings promising 90 and 95 percent effectiveness against the virus, respectively, attention now turns to mass production and, more importantly, mass distribution. According to Anna Nagurney, Ph.D., Director of the Virtual Center for Supernetworks and professor at the Department of Operations and Information Management at the University of Massachusetts, distribution is where the biggest challenges lie.
With COVID-19 cases rising across the country, the need for a safe and reliable vaccine is increasing. Both Pfizer and Moderna have announced vaccine trials with more than 90% effectiveness. Creating vaccines and getting federal approval are only the first hurdles which are followed by finding ways to transport the highly-perishable vaccines to millions of Americans.
OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.
Access OR/MS Today Magazine
Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.
Access Analytics Magazine
